GPRC5D-Targeted CAR T Cells for MyelomaSham Mailankody, Eric L. Smith, Romany Auclair et al.|New England Journal of Medicine|2022Cited by 383
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple MyelomaOla Landgren, Neha Korde, Malin Hultcrantz et al.|JAMA Oncology|2021Cited by 119
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Ola Landgren, Neha Korde et al.|The Lancet Haematology|2021Cited by 95